AHI1: A Drug Target / Disease Biomarker (G54806)

Target Name: AHI1

NCBI ID: G54806

AHI1: A Drug Target / Disease Biomarker

AHI1, short for Abelson helper integration site 1, is a protein that is associated with the development and progression of Alzheimer's disease (AD). It is a transmembrane protein that is expressed in the brain and is involved in the formation of beta-amyloid plaques, which are a hallmark of AD.

One of the unique features of AHI1 is its ability to interact with the protein tau, another protein that is also associated with the development of AD. When AHI1 binds to tau, it can cause tau to form aggregates that are toxic to nerve cells, leading to the development of neurodegeneration.

The search for new drug targets and biomarkers for AD has led to the study of AHI1 and its potential as a drug target. One of the main advantages of AHI1 is its high expression level, which makes it an attractive target for drug development. Additionally, because AHI1 is involved in the formation of beta-amyloid plaques, it is a potential biomarker for the early stages of AD.

There is currently no cure for AD, and the only way to treat the disease is to manage its symptoms. However, new research has shown that AHI1 may be a promising drug target for AD. Studies have shown that inhibiting AHI1 can reduce the formation of beta-amyloid plaques and improve cognitive function in AD patients.

One of the main challenges in developing a treatment for AD is the development of resistance to the currently available treatments. This is because AD is a progressive disease that is characterized by the buildup of beta-amyloid plaques, which can be difficult to target. However, AHI1 may be an attractive target for AD because its interaction with tau makes it a potential target for drugs that can inhibit the formation of beta-amyloid plaques.

In conclusion, AHI1 is a protein that is associated with the development and progression of AD. Its high expression level and interaction with tau make it an attractive target for drug development. Currently, there is no cure for AD, but new research has shown that inhibiting AHI1 may be a promising way to treat the disease.

Protein Name: Abelson Helper Integration Site 1

Functions: Involved in vesicle trafficking and required for ciliogenesis, formation of primary non-motile cilium, and recruitment of RAB8A to the basal body of primary cilium. Component of the tectonic-like complex, a complex localized at the transition zone of primary cilia and acting as a barrier that prevents diffusion of transmembrane proteins between the cilia and plasma membranes. Involved in neuronal differentiation. As a positive modulator of classical Wnt signaling, may play a crucial role in ciliary signaling during cerebellum embryonic development (PubMed:21623382)

More Common Targets